With NARD's contract synthesis, contract manufacture, and contract research services, we will help you overcome challenges in research and development.
We have proven experience of research and development in many fields, including pharmaceuticals, organic electroluminescent materials, organic semiconductors, and battery materials.
We have a wide-ranged product line-up in stock.
The minimum amount for ordering is 10mg. Most of our PET / SPECT Chemicals purity is higher than 98%. The delivery time of our PET Chemicals in stock will be short. All our products are provided with the certification of analysis including HPLC charts, 1H-NMR spectra data and so on.
The items listed in the Catalogue (PET/SPECT) will be updated at any time. Please contact us by E-mail.
One of our most important service for the clients is Custom Synthesis. We are able to offer specially-ordered compounds for PET / SPECT. Regarding an inquiry for any reagent that is not listed in the Catalogue, it is possible to receive as a special order.
We also have experiences to manufacture PET chemicals in accordance with Good manufacturing practice (GMP) standard in NARD Chemicals, Ltd., which is our subsidiary company.
Catalogue No. NP034-0
Effect of Aging on Muscarinic Receptors in the Monkey Brain as Measured by [11C] (+)3-MPB
*Image Data of products jointly developed by Hamamatsu Photonics K.K.
Tsukada et al., Synapse (2001a, b); Nishiyama et al., Synapse (2001)
Catalogue No. NP076-0
Start the exclusive sales of PBB3 (new PET ligands of tau pathology)
We are proud to announce that we concluded an exclusive licensing agreement for commercialization of PBB3, Pre3 and DMPBB3 with National Institute of Radiological Sciences (NIRS).
Three compounds, which are referential standard compounds and precursor, are now able to be supplied only in research applications from NARD Institute, Ltd..
We hope that studies for PET of tau pathology becomes more active through the use of [11C]PBB3.
Structure of PBB3, Pre3 and DMPBB3
[11C]PBB3 ([11C]pyridinyl-butazienyl-benzothiazole; IUPAC name, 2-((1E,3E)-4-(6-([11C]methylamino)pyridin-3-yl)buta-1,3-dienyl)benzo[d]thiazol-6-ol) is a radioactive compound applicable to positron emission tomography (PET) imaging of tau protein aggregates in living brains.1) Tau lesions, as exemplified by neurofibrillary tangles in Alzheimer’s disease (AD), are characteristic of diverse neurodegenerative dementias, and are known to tightly correlate with neuronal death in these illnesses. [11C]PBB3 reacts with tau deposits in AD with high affinity (KD = 2.5 nM) and selectivity (tau : Aβ = 120 : 1) according to an autoradiographic binding assay.1) Using an established radiolabeling protocol,2) [11C]PBB3 can be synthesized with reasonably high yield, and has been demonstrated to visualize tau pathologies in AD and non-AD dementias.1) An exploratory clinical PET study also indicated the capability of [11C]PBB3 in pursuing tau accumulation spreading in progression from prodromal to advanced stages of AD.1) Moreover, [11C]PBB3 binds to tau inclusions in transgenic mouse models of tau pathologies,1) enabling translational research and development of diagnostic and therapeutic drug candidates targeting tau lesions. To avoid conversion to its photoisomers, radiosynthesis and injection of [11C]PBB3 should be performed in a dimly lit facility.2)
1) Maruyama et al. Neuron 79, 1094 – 1108, 2013.
2) Hashimoto et al. J Nucl Med 55, 1532-1538, 2014.
Legend for figure
Coronal PET images of brains healthy control (HC) and patient with Alzheimer's disease (AD) at 30 – 70 min after intravenous administration of [11C]PBB3. PET data are superimposed on individual 3D MRI anatomical maps. Intense radiosignals are observed in tau-rich regions including the bilateral hippocampal formations (arrowheads) of the AD brain. Images provided by National Institute of Radiological Sciences.
Catalogue No. NC003-0 & NC006-0
Reagents for 11C radiochemistry of high specific radioactivity
NARD Institute, Ltd. was established in 1972 by creating a new business model called contract research company in the field of chemistry in Japan. We have started synthesis of specially-ordered PET chemicals since 1995, and have accumulated the synthetic experiences of many precursors and cold standard compounds.
Furthermore, in 2006 we entered into the business tie-up with PharmaSynth AS (Estonia) and since then we have been developing business of distributing PET chemicals that have been produced by both companies, on the global market. Both companies have currently been distributing PET / SPECT precursors that are for general use, as well as cold standard compounds.
Please be inquiry for us about price, delivery time, quantity and inventory.
Please contact us for more information about products and services.
NARD INSTITUTE, LTD. Corporate Group
5-4-1, Minatojimaminami-machi, Chuou-ku, Kobe, Hyogo 650-0047 Japan, JAPAN